Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STA551 phase Ia/Ib dose-escalation study alone and with atezolizumab in advanced solid tumors
jRCT2080225058Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of STA551 and atezolizumab in Nonhematologic neoplasms (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and Pharmacokinetics. Started Feb 2020; status: completed.
02
Drugs
STA551atezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080225058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225058.